HKEX announces record half-yearly revenue of HK$8.2billion (+32% YoY)
HKEX reached a number of milestones in the first half of the year including strong growth in trading volumes, +67% YoY and +58% YoY in the cash market and futures and options respectively. The first WVR company and pre-revenue Biotech companies under the new regime listed and HKEX reached a consensus with Mainland exchanges on the inclusion of WVR companies in Stock Connect South Bound trading. And Stock Connect continued to gather momentum after the expansion of the daily quota in May and the inclusion of A-shares in MSCI Emerging Market Index in June.
RISK DISCLAIMER: Trading in futures products entails significant risks of loss which must be understood prior to trading and may not be appropriate for all investors. Past performance of actual trades or strategies cited herein is not necessarily indicative of future performance. The information contained herein is provided to you for information only and believed to be drawn from reliable sources but cannot be guaranteed; Phillip Capital Inc. assumes no responsibility for errors or omissions. The views and opinions expressed in this letter are those of the author and do not reflect the views of Phillip Capital Inc. or its staff.